These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12702571)

  • 1. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
    Nunes M; Kaplan J; Wooters J; Hari M; Minnick AA; May MK; Shi C; Musto S; Beyer C; Krishnamurthy G; Qiu Y; Loganzo F; Ayral-Kaloustian S; Zask A; Greenberger LM
    Biochemistry; 2005 May; 44(18):6844-57. PubMed ID: 15865430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).
    Zask A; Birnberg G; Cheung K; Kaplan J; Niu C; Norton E; Suayan R; Yamashita A; Cole D; Tang Z; Krishnamurthy G; Williamson R; Khafizova G; Musto S; Hernandez R; Annable T; Yang X; Discafani C; Beyer C; Greenberger LM; Loganzo F; Ayral-Kaloustian S
    J Med Chem; 2004 Sep; 47(19):4774-86. PubMed ID: 15341492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
    Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
    Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
    Loganzo F; Hari M; Annable T; Tan X; Morilla DB; Musto S; Zask A; Kaplan J; Minnick AA; May MK; Ayral-Kaloustian S; Poruchynsky MS; Fojo T; Greenberger LM
    Mol Cancer Ther; 2004 Oct; 3(10):1319-27. PubMed ID: 15486199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.
    Liu J; Towle MJ; Cheng H; Saxton P; Reardon C; Wu J; Murphy EA; Kuznetsov G; Johannes CW; Tremblay MR; Zhao H; Pesant M; Fang FG; Vermeulen MW; Gallagher BM; Littlefield BA
    Anticancer Res; 2007; 27(3B):1509-18. PubMed ID: 17595769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
    Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
    Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
    Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.
    Krishnamurthy G; Cheng W; Lo MC; Aulabaugh A; Razinkov V; Ding W; Loganzo F; Zask A; Ellestad G
    Biochemistry; 2003 Nov; 42(46):13484-95. PubMed ID: 14621994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
    Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
    Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.
    Zask A; Kaplan J; Musto S; Loganzo F
    J Am Chem Soc; 2005 Dec; 127(50):17667-71. PubMed ID: 16351096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
    Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.